Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
De-escalation of Axillary and Breast Cancer Surgery in the Setting...
share announcement

De-escalation of Axillary and Breast Cancer Surgery in the Setting of Neo-Adjuvant Chemotherapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 November 2024 | Viewed by 665

Special Issue Editors

Prof. Dr. Corrado Tinterri

E-Mail Website
Guest Editor
1. Breast Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
2. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy
Interests: breast; breast neoplasm; breast cancer; surgery; breast cancer surgery; axilla; axillary surgery
Dr. Damiano Gentile

E-Mail Website
Guest Editor
1. Breast Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
2. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy
Interests: breast; breast neoplasm; breast cancer; surgery; breast cancer surgery; axilla; axillary surgery

Special Issue Information

Dear Colleagues,

In recent years, the paradigm of breast cancer (BC) treatment has witnessed significant shifts, especially in the approach to surgical intervention following neo-adjuvant chemotherapy (NAC). Historically, radical surgeries like mastectomy and extensive axillary lymph node dissection were the cornerstones of BC management. However, the introduction and success of NAC have opened avenues for less aggressive surgical techniques, marking a transition towards de-escalation in surgical management. This shift not only aligns with the principles of conservative surgery but also addresses the physical and psychological burdens experienced by patients. The efficacy of NAC in downstaging tumors has provided a compelling rationale for re-evaluating the necessity and extent of subsequent surgeries. In patients exhibiting a favorable or complete response to NAC, the feasibility of less invasive procedures like breast-conserving surgery, sentinel lymph node biopsy, or the omission of surgery altogether is being increasingly considered. The central tenet of this discussion lies in the careful balance between ensuring oncological safety and reducing the morbidity associated with traditional surgical approaches.

Prof. Dr. Corrado Tinterri
Dr. Damiano Gentile
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast neoplasm
  • breast cancer
  • surgery
  • breast cancer surgery
  • systemic therapy
  • neo-adjuvant chemotherapy
  • axilla
  • axillary surgery
  • sentinel lymph node biopsy
  • de-escalation surgery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 900 KiB  
Article
De-Escalation Surgery in cT3-4 Breast Cancer Patients after Neoadjuvant Therapy: Predictors of Breast Conservation and Comparison of Long-Term Oncological Outcomes with Mastectomy
by Corrado Tinterri, Erika Barbieri, Andrea Sagona, Alberto Bottini, Giuseppe Canavese and Damiano Gentile
Cancers 2024, 16(6), 1169; https://doi.org/10.3390/cancers16061169 - 16 Mar 2024
Viewed by 552
Abstract
Background: Neoadjuvant therapy (NAT) has become increasingly employed for the treatment of cT3-4 breast cancer (BC), enabling breast-conserving surgery (BCS) in cases traditionally considered for mastectomy. This study aims to identify predictors for breast conservation post-NAT and to evaluate whether BCS influences long-term [...] Read more.
Background: Neoadjuvant therapy (NAT) has become increasingly employed for the treatment of cT3-4 breast cancer (BC), enabling breast-conserving surgery (BCS) in cases traditionally considered for mastectomy. This study aims to identify predictors for breast conservation post-NAT and to evaluate whether BCS influences long-term oncological outcomes. Methods: We retrospectively analyzed data from patients with cT3-4 BC who received NAT at the Breast Unit of IRCCS Humanitas Research Hospital, Milan, Italy, from October 2009 to April 2020. Surgical outcomes and long-term oncological results, such as disease-free survival (DFS), distant DFS (DDFS), overall survival (OS), and BC-specific survival (BCSS), were compared between the BCS and mastectomy groups. Results: Among 114 patients analyzed, 37 (32.5%) underwent BCS, and 77 (67.5%) had a mastectomy. The key predictors for opting for BCS included absence of vascular invasion, reduced tumor size post-NAT, and achieving ypT0 status. No significant differences in DFS, DDFS, OS, and BCSS were observed between the two surgical groups (log-ranks, p = 0.520, p = 0.789, p = 0.216, p = 0.559, respectively). Conclusions: BCS after NAT is a feasible and safe option for patients with cT3-4 BC, without adversely affecting long-term oncological outcomes. Identifying predictors of breast conservation can guide surgical decision-making, ensuring that patients receive optimal treatment. Full article
(This article belongs to the Special Issue De-escalation of Axillary and Breast Cancer Surgery in the Setting of Neo-Adjuvant Chemotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop